AffiliationInnovative Immunotherapies Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Hospital Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.
MetadataShow full item record
AbstractThe recent successes of clinical trials with T cells genetically modified with either clonal T cell receptors or chimeric antigen receptors have also highlighted their potential toxicities. The aim of this focused review was to describe the adverse events observed in these clinical trials and to link them to the complex biology of genetically targeted T cells. Finally, strategies to overcome these toxicities will be proposed and discussed, including the use of suicide genes and other innovative gene therapy strategies.
CitationOvercoming the toxicity hurdles of genetically targeted T cells. 2015, 64 (1):123-30 Cancer Immunol Immunother
JournalCancer Immunology, Immunotherapy
- Biomarkers in T-cell therapy clinical trials.
- Authors: Lacey SF, Kalos M
- Issue date: 2013 Jun
- Multi-cistronic vector encoding optimized safety switch for adoptive therapy with T-cell receptor-modified T cells.
- Authors: van Loenen MM, de Boer R, Hagedoorn RS, Jankipersadsing V, Amir AL, Falkenburg JH, Heemskerk MH
- Issue date: 2013 Aug
- Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
- Authors: EFSA GMO Panel Working Group on Animal Feeding Trials.
- Issue date: 2008 Mar
- Cancer therapy with genetically-modified T cells for the treatment of melanoma.
- Authors: Lagisetty KH, Morgan RA
- Issue date: 2012 Jun
- Improving the efficacy and safety of engineered T cell therapy for cancer.
- Authors: Shi H, Liu L, Wang Z
- Issue date: 2013 Jan 28